IPO
이노보테라퓨틱스
What the company does
InnoVo Therapeutics is a synthetic drug developer that uses its AI-based drug discovery platform DeepZema to develop small-molecule candidates for immune, inflammatory, fibrotic and cancer diseases. The company out-licenses its candidates to pharmaceutical partners, with INV-008 licensed to Daewoong Pharmaceutical in 2026.
Themes:Biotech (new drugs)
- Market
- KOSDAQ
- Price range
- ₩20,000 – ₩24,000
- Offer price
- Not set yet
- Subscription
- Dec 7 – Dec 8
- Payment date
- Dec 10, 2026
- Listing
- Not set yet
- Shares offered
- 2,200,000
- Raising
- ₩44B
Lead managers: Korea Investment & Securities
Filings
- 증권신고서(지분증권)Oct 21, 2026Open on DART ↗
How a Korean IPO works: institutions bid first (the demand forecast), which sets the final offer price; then individuals subscribe for two days through the lead managers' brokerage accounts; shares start trading on the listing date.
Dates and prices can change until the final terms are filed. Not financial advice. · Updated Oct 27, 2026 · IPO calendar